CN118678950A - 用于治疗阿尔茨海默氏病的alz-801 - Google Patents
用于治疗阿尔茨海默氏病的alz-801 Download PDFInfo
- Publication number
- CN118678950A CN118678950A CN202280091217.0A CN202280091217A CN118678950A CN 118678950 A CN118678950 A CN 118678950A CN 202280091217 A CN202280091217 A CN 202280091217A CN 118678950 A CN118678950 A CN 118678950A
- Authority
- CN
- China
- Prior art keywords
- dose
- alz
- day
- subject
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163287552P | 2021-12-09 | 2021-12-09 | |
| US63/287,552 | 2021-12-09 | ||
| PCT/US2022/052331 WO2023107658A1 (en) | 2021-12-09 | 2022-12-09 | Alz-801 for use in treating alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118678950A true CN118678950A (zh) | 2024-09-20 |
Family
ID=85157530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280091217.0A Pending CN118678950A (zh) | 2021-12-09 | 2022-12-09 | 用于治疗阿尔茨海默氏病的alz-801 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250041248A1 (enExample) |
| EP (1) | EP4444286A1 (enExample) |
| JP (1) | JP2024542844A (enExample) |
| KR (1) | KR20240116529A (enExample) |
| CN (1) | CN118678950A (enExample) |
| AU (1) | AU2022405026A1 (enExample) |
| CA (1) | CA3240392A1 (enExample) |
| IL (1) | IL313404A (enExample) |
| MX (1) | MX2024007070A (enExample) |
| WO (1) | WO2023107658A1 (enExample) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3347002T (pt) * | 2015-09-10 | 2023-07-27 | Alzheon Inc | Tratamento de doença de alzheimer numa população particular de pacientes |
| DK3829563T3 (en) * | 2018-08-01 | 2025-02-24 | Alzheon Inc | 3-sulfopropanoic acid for treating neurodegenerative disorders |
-
2022
- 2022-12-09 IL IL313404A patent/IL313404A/en unknown
- 2022-12-09 MX MX2024007070A patent/MX2024007070A/es unknown
- 2022-12-09 CN CN202280091217.0A patent/CN118678950A/zh active Pending
- 2022-12-09 WO PCT/US2022/052331 patent/WO2023107658A1/en not_active Ceased
- 2022-12-09 EP EP22851094.7A patent/EP4444286A1/en active Pending
- 2022-12-09 US US18/717,139 patent/US20250041248A1/en active Pending
- 2022-12-09 CA CA3240392A patent/CA3240392A1/en active Pending
- 2022-12-09 JP JP2024534268A patent/JP2024542844A/ja active Pending
- 2022-12-09 AU AU2022405026A patent/AU2022405026A1/en active Pending
- 2022-12-09 KR KR1020247022383A patent/KR20240116529A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022405026A1 (en) | 2024-06-20 |
| JP2024542844A (ja) | 2024-11-15 |
| EP4444286A1 (en) | 2024-10-16 |
| IL313404A (en) | 2024-08-01 |
| CA3240392A1 (en) | 2023-06-15 |
| WO2023107658A1 (en) | 2023-06-15 |
| US20250041248A1 (en) | 2025-02-06 |
| KR20240116529A (ko) | 2024-07-29 |
| MX2024007070A (es) | 2024-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5289765B2 (ja) | 自閉症、強迫神経症、および衝動性の治療のためのメマンチン（ナメンダ）の使用 | |
| MADSEN et al. | Hypophysectomy for diabetic angiopathy: a controlled clinical trial | |
| KR20190142364A (ko) | 펜플루라민을 사용하여 두즈 증후군을 치료하는 방법 | |
| CN114423416A (zh) | Syngap1脑病的治疗 | |
| ES3062607T3 (en) | Cannabinoid composition and application thereof in preparation of drug for treating neurodegenerative diseases such as parkinson's disease and alzheimer's disease | |
| JP2019052176A (ja) | スタンソポルフィンを含有する、乳児における高ビリルビン血症又はその症状の治療のための薬剤 | |
| MD3347002T2 (ro) | Tratamentul bolii Alzheimer într-o populație specifică de pacienți | |
| CN114786660A (zh) | 使用mtorc1调节剂的治疗方法 | |
| US20100035927A1 (en) | Medicament for prophylactic and/or therapeutic treatment of alzheimer-type dementia | |
| KR20120050473A (ko) | 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도 | |
| CN1332667C (zh) | 一种抗帕金森症（pd）复合制剂 | |
| Mulnard et al. | Estrogen replacement therapy, Alzheimer’s disease, and mild cognitive impairment | |
| JP2013032308A (ja) | うつ病治療用または予防用医薬組成物 | |
| US20250041248A1 (en) | Alz-801 for use in treating alzheimer's disease | |
| CN110538178A (zh) | 氢溴酸樟柳碱在制备治疗脑小血管病相关认知功能障碍的药物中的用途 | |
| Bowles et al. | Randomized double-blind placebo-controlled comparison of nicardipine and nifedipine in patients with chronic stable angina pectoris | |
| CN105287985A (zh) | 药物组合物在制备防治老年痴呆的药物中的应用 | |
| EP0707477B1 (fr) | Utilisation de l'efaroxan et de ses derives pour la fabrication de medicaments destines au traitement des maladies neurodegeneratives | |
| Tariot et al. | Anticonvulsants to treat agitation in dementia | |
| CN1332666C (zh) | 一种抗老年痴呆症复合制剂 | |
| RU2670205C1 (ru) | Способ премедикации больных с нарушениями ритма сердца при стоматологическом вмешательстве | |
| JP2007532624A (ja) | アルツハイマー病の治療のための療法組合せ | |
| Cregler | Progression from hypertrophic cardiomyopathy to dilated cardiomyopathy | |
| Rafiq | Isolated periorbital angio-oedema induced by aspirin: a case report and review of the literature | |
| WO2025018279A1 (ja) | ヒト移植片対宿主病の治療薬およびその組合せ物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |